September 30, 2021
August 30, 2021
Ophthalmology Times Europe Journal, Ophthalmology Times Europe September 2021, Volume 17, Issue 07
For ophthalmologists, finding the ideal solution for presbyopia has long been the ‘holy grail’ of the field.
Presbyopia is a natural consequence of ageing. It affects more than 1 billion individuals globally and approximately 123 million in the United States. Over the years, many surgical approaches to the correction of the condition have been attempted, but none has yet become widely adopted for patients without significant cataract.
A review of available and emerging treatments for presbyopia was recently published.1 Finding the ultimate solution for this problem has long been the holy grail of ophthalmology because the demand—and the potential rewards—are great.
Companies have begun testing topical therapies for the temporary correction of presbyopia. Several of these drugs may be approved over the next 1 to 3 years, opening a new treatment avenue for patients who wish to be less dependent on reading glasses.
Most of the drops being evaluated aim to modulate the pupil for better near vision. There are likely to be significant differences among them in duration, tolerability and other factors.